About the Company
reata pharmaceuticals, inc. (nasdaq:reta) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $RETA News
Reata Pharmaceuticals Stock Plummets More Than 20%: Here's Why
Reata Pharmaceuticals Inc (NASDAQ: RETA) and its partner Kyowa Kirin Co Ltd have decided to discontinue bardoxolone chronic kidney disease programs. In May 2023, Kyowa Kirin announced data from ...
Biogen To Buy Plano-Based Reata Pharmaceuticals
Biogen Inc. plans to acquire Plano-based Reata Pharmaceuticals Inc. for $7.2 billion. This is Biogen’s first acquisition since Christopher Viehbacher took over as CEO. This week, the company ...
Reata Pharmaceuticals Inc Class A
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / February 29, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Reata Pharmaceuticals ...
Reata Pharmaceuticals gets grant for biaryl amides and coumarin-based compounds for treating diseases
Discover Reata Pharmaceuticals' groundbreaking patent for biaryl amides and coumarin-based compounds targeting neurological disorders and diabetic neuropathy. Explore the innovative formula and ...
Reata Pharmaceuticals
Projects include: 3401 & 3501 Olympus Blvd, HQ53, Reata Pharmaceuticals, The Offices Two at Frisco Station, and Victory Commons One. North Texas corporate lawyers share insights about moving ...
AbbVie Inc.'s Net Worth
AbbVie Inc. has an estimated net worth of $10.1 Million. This is based on reported shares in REATA PHARMACEUTICALS INC. Attention insiders: Dive deeper into market movements and stay ahead of the ...
Why Is Biogen Inc. (BIIB) Up 2.6% Since Last Earnings Report?
It has been about a month since the last earnings report for Biogen Inc. (BIIB ... was added with the September 2023 acquisition of Reata Pharmaceuticals, generated sales of $55.9 million ...
Biogen Completes Acquisition of Reata Pharmaceuticals
Biogen Inc. (Nasdaq: BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a company focused on developing therapeutics that regulate cellular metabolism and ...
Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / March 12, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class ...
Loading the latest forecasts...